Yesterday, we shared our 17 year journey with myeloma with the wonderful folks at @bluebirdbio in Cambridge, MA. There were 300+ Researchers in the room plus they did a live feed to their office in Seattle too! We also met with their Oncology Clinical, Regulatory & Program teams, then their Immunotherapy Research Team! We were extremely impressed with this company’s young, passionate and extremely qualified staff. Everyone is working diligently towards a cure for #myeloma!
Right now, their myeloma study is the CRB-401 Phase 1 study and is assessing the safety and effectiveness of CAR T Cell Therapy as a treatment for multiple myeloma. CAR T Cell Therapy uses gene therapy to modify a person’s own white blood cells (T cells) to attack the cancerous myeloma cells.
Thanks to these passionate researchers and we hope to read more about their trial at ASH 2017!